RLAY - Relay Therapeutics rallies 7% on EcoR1 pitch

Relay Therapeutics ([[RLAY]] +7.3%) is up, albeit on below-average volume, in apparent response to a presentation on the company by fundamental shop EcoR1 Capital at the Sohn Conference.The company debuted on July 16 at $20. Shares are currently exchanging hands at $47.13, up 136%.It develops small molecule therapies leveraging its know-how in protein motion. Its Dynamo platform, which integrates experimental and computational approaches, enables it to more effectively identify previously undruggable protein targets.Lead candidates are RLY-1971, an inhibitor of a protein called SHP2 (Src homology region 2 domain-containing phosphatase-2), and RLY-4008, an inhibitor of a protein called fibroblast growth factor receptor 2 (FGFR2), both in Phase 1 development for the potential treatment of solid tumors.SA Authors are Bullish.

For further details see:

Relay Therapeutics rallies 7% on EcoR1 pitch